RIPK1 inhibitors are drugs that target the enzyme RIPK1, crucial in cell death and inflammation regulation.

Connect Biopharma has revealed encouraging primary outcomes from its global Phase 2b trial of Rademikibart in treating adults with moderate to severe chronic asthma.

post marketing research of drugs refers to the research on the use and effect of drugs following a specific research scheme after they are approved for marketing.

GigaGen Inc. has announced FDA approval for its IND application. This permits the start of a Phase 1 trial to evaluate GIGA-564's effectiveness in treating diverse solid cancers.

Protein kinase inhibitors are drugs that target protein kinases, crucial in cell signaling and regulation. The future sees potential applications in treating various diseases, particularly cancer.

Biotech company UNITY Biotechnology has launched its Phase 2 ASPIRE trial, administering its aging-focused drug UBX1325 (foselutoclax) to the first patients.

Antibody sequences can be identified via PCR, NGS, and bioinformatics analysis tools.

Mabwell announced its Phase III trial application for 9MW2821 vs. standard chemo in advanced urothelial carcinoma.

Due to the important role that arginine methylation plays in the development of cancer, PRMT5 has become a potential target for cancer treatment.

Hemab Therapeutics has reported the initial dosing of a participant in a Stage 2 medical trial assessing the efficacy of HMB-001 in addressing Glanzmann's Thrombasthenia.

The exact number of protein sequence variants caused by post-translational modifications (PTMs), which alter proteins after synthesis, is unclear.

NAYA Biosciences Reveals New Findings on Its CD38-Directed Flex-NK™ Dual-Specific Antibody in the Journal Published by the American Society of Hematology.